Paper Review — Claim-Level

 Quick Explanation Copied

 Long Explanation

What the paper reports

Liu et al. isolated CAFs and normal fibroblasts (NFs) from 5 radical-prostatectomy patients and showed CAFs express higher α-SMA/Vimentin, more LC3B puncta, higher Beclin1 and LC3II/I, and lower p62 than NFs. Conditioned medium (CM) from CAFs, but not NFs, increased PC-3/DU145 proliferation, migration, and invasion; these effects were reversed by the autophagy inhibitor 3-MA or by ATG5 siRNA in CAFs, and mimicked by ATG5 overexpression in NFs. In vivo, PC-3 + CAF xenografts grew faster and produced more lung nodules than PC-3 + NFs, and si-ATG5 in CAFs abrogated both Primary paper: CAF autophagy drives PCa phenotypes.

Critical appraisal

• ATG5 dependency is not fully established. DU145 cells lack functional ATG5 in prior work Piperine PCa study noting DU145 ATG5 deficiency, yet this paper uses DU145-CM responses as evidence of ATG5-dependent effects; the authors did not address this, so DU145 data cannot cleanly support an ATG5 mechanism.
• 3-MA specificity. 3-MA also inhibits PI3K/mTOR-related pathways beyond autophagy; no independent autophagy inhibitor or ATG rescue was performed, so the 3-MA arm is supportive but not decisive.
• Correlation vs. causation of the secreted factor. The paper never identifies the pro-tumor mediator of CAF-CM (e.g., HMGB1 was implicated in NSCLC CAFs Prior CAF-autophagy mechanism in NSCLC); the effect on PCa cells could reflect any CM component modulated by CAF metabolism, not necessarily ATG5 itself.
• Small, single-institution cohort (n=5 patients) and only androgen-insensitive lines (PC-3, DU145) restrict generalizability; the authors acknowledge the androgen-receptor caveat and lack of reciprocal PCa-CM-to-fibroblast experiments Author-stated limitations.

Confidence: moderate. The in vivo ATG5 knockdown rescue is the strongest element; autophagy pharmacology and the unidentified secreted mediator are the weakest links. Findings would be falsified if an ATG5-independent CAF secretome change recapitulated all phenotypes without altering LC3 flux.

 BGPT Paper Review

Study Novelty

Extends established CAF-autophagy→tumor-promotion findings (breast, bladder, NSCLC) to prostate cancer with ATG5 as the mediator; incremental rather than groundbreaking.

Scientific Quality

Logical gain/loss-of-function design with in vivo confirmation, but tiny patient cohort (n=5), off-target-prone 3-MA, ATG5-null DU145 unaddressed, and unidentified secreted mediator weaken causal claims; no raw data deposition.

Study Generality

Mechanistic finding may extend to other CAF-rich tumors, but conclusion is anchored to PC-3/DU145 and androgen-insensitive PCa context only.

Study Usefulness

Suggests CAF ATG5 as a stromal therapeutic target for PCa progression, informing TME-directed combination strategies, though preclinical only.

Study Reproducibility

Methods (passages 2-6, 5 mM 3-MA, siRNA sequences in supplement) are reasonably detailed; no public data or code, and single-center tissue source limits independent replication.

Explanatory Depth

Correlative autophagy marker changes (LC3II/I, Beclin1, p62) plus ATG5 perturbation, but the downstream molecular effector linking CAF autophagy to PCa malignancy is never identified.